GLP-1 Buyer Safety Hub
How to Spot a Legitimate GLP-1 Clinic Online (2026)
Online GLP-1 clinics range from rigorously vetted medical programs to barely-legal shortcut operations. Before you submit your credit card, here are the five signals that separate a safe telehealth provider from a risky one — and the red flags that should make you walk away.
Last updated August 2026 · Independent editorial, no clinician input required.
5 signals of a legitimate GLP-1 clinic
LegitScript Certified
LegitScript independently verifies that online pharmacies and telehealth platforms meet legal and safety standards. A LegitScript seal means the clinic has been audited — the absence of one is a transparency gap worth noting.
Licensed 503A Pharmacy
All compounded semaglutide and tirzepatide dispensed by our ranked clinics comes from state-licensed 503A compounding pharmacies operating under USP 797 sterility standards — not unlicensed gray-market sources.
US Board-Certified Clinicians
Legitimate programs require a real clinician review — a licensed physician or NP in your state who can legally prescribe, assess contraindications, and adjust your dose. Questionnaire-only auto-approval is a red flag.
HIPAA-Compliant Platform
Your medical history and payment data should travel over a HIPAA-compliant system. Any GLP-1 platform that does not explicitly affirm HIPAA compliance is cutting corners on your privacy.
Transparent All-In Pricing
Safe clinics show you the full monthly cost — medication, consultation, and shipping — before you commit. Watch for 'as low as' bait-and-switch headlines that reflect only the smallest starting dose on the longest commitment plan.
State Delivery Confirmation
Compounding regulations vary by state. A reputable clinic confirms delivery to your specific state during the intake process, or publishes an explicit list. Generic '50-state' claims without documentation deserve verification.
Red flags — walk away if you see these
No clinician intake review
Any platform that ships GLP-1 medication without a licensed clinician reviewing your medical history is operating outside the law. A legitimate program requires a real intake, not a quick questionnaire with automatic approval.
No LegitScript certification disclosed
LegitScript certification isn't required by law, but its absence — especially combined with other opacity signals — should prompt extra scrutiny. Ask directly if the dispensing pharmacy is LegitScript-verified.
Pricing far below market without explanation
Compounded semaglutide below roughly $90/month usually means lower-grade sourcing, shorter supply chains, or hidden step-up pricing. The cheapest headline price is often not the real monthly cost.
Billing surprises and hard-to-cancel subscriptions
The most common BBB complaints in GLP-1 telehealth involve unexpected charges and difficult cancellations. Read the cancellation policy before you submit payment — if it isn't clearly published, that tells you something.
Offshore or unlicensed pharmacy sourcing
Compounded semaglutide and tirzepatide dispensed from outside the US or from unlicensed facilities carries unknown potency and sterility risks. Ask explicitly where your medication is compounded.
No state list or vague 'all states' claims
Not every clinic can legally serve every state. If a site claims nationwide availability without specifying state restrictions, verify directly — some states have active restrictions on telehealth prescribing for compounded GLP-1.
5 questions to ask before you pay
Any reputable clinic answers all five without hesitation. Evasiveness on any of these is itself a signal.
- 1
Is the dispensing pharmacy LegitScript-certified? (Ask for the certification number — legitimate clinics provide it.)
- 2
Is my medication compounded by a licensed 503A pharmacy? Where is it located?
- 3
Who will review my medical intake — a licensed physician or NP? Are they licensed in my state?
- 4
What is the full monthly cost at the maintenance dose, including medication, consultations, and shipping?
- 5
What is your cancellation policy, and how do I stop shipments if I need to pause?
How our independent ratings apply this checklist
Our scoring methodology weights Transparency & Trust at 15%of each clinic's total score. LegitScript certification, pharmacy model disclosure, pricing transparency, and published state lists all feed into this dimension. A clinic that refuses to answer these five questions cannot score above 7.0/10 on our rubric — and we say so in the individual review. See our full ranking and individual reviews — for example, Wellorithm, Gala Health, and Yucca Health — to see how each clinic scores on these four criteria.
Medical safety basics
Separate from vetting the clinic, understand the medication itself. GLP-1 drugs are well-studied and safe for most eligible adults under proper clinical supervision. FDA compounding guidance is the authoritative source on compounded GLP-1.
Common side effects
Nausea, vomiting, diarrhea, constipation, and reflux are the most common — usually worst early and easing with slow dose titration.
Who should not take GLP-1
A personal or family history of medullary thyroid carcinoma or MEN2, and pregnancy or planning pregnancy, generally rule out GLP-1 therapy.
Pancreatitis history
A prior history of pancreatitis warrants caution. Tell your clinician so they can weigh risks before prescribing.
Slow titration matters
Doses are stepped up gradually. Rushing the schedule drives the worst nausea — a good clinic titrates, it does not max you out.
Compounded vs brand-name
Compounded semaglutide and tirzepatide are widely available via telehealth. Understand the sourcing, labeling, and trade-offs versus brand-name Wegovy or Zepbound before choosing.
Prescription-only medication
Semaglutide and tirzepatide require a prescription and a licensed clinician who reviews your eligibility, monitors your progress, and adjusts your dose as needed.
What the research says
We don't employ a medical reviewer, so instead of claiming clinical authority we haven't earned, we cite the actual named researchers and regulators publishing on GLP-1 safety and supply.
Dr. Daniel J. Drucker
Lunenfeld-Tanenbaum Research Institute, University of Toronto — co-discoverer of GLP-1 biology
Reviewed the expanding evidence base for GLP-1 medicines beyond weight loss, including cardiovascular and kidney-disease benefits, alongside open questions on long-term safety that still require more data.
“GLP-1-based therapies for diabetes, obesity and beyond,” Nature Reviews Drug Discovery / Nature Medicine, 2025 →Prof. Naveed Sattar
School of Cardiovascular & Metabolic Health, University of Glasgow
Co-authored 2025 analysis showing tirzepatide produces dose-dependent weight reductions of roughly 10–25% alongside measurable cardiometabolic benefit in adults with obesity.
“From Weight Loss to Multimorbidity Prevention: Framing the Anticipated Contributions of SURMOUNT-MMO,” 2025 →U.S. Food & Drug Administration
Federal regulator overseeing drug compounding
Declared the national semaglutide shortage resolved (Feb 2025) and the tirzepatide shortage resolved (Dec 2024), then set phased enforcement deadlines curbing mass compounding of both drugs now that branded supply has stabilized — a key reason to ask any clinic exactly which pharmacy compounds your prescription and under what exemption.
FDA drug shortage & compounding policy statements, 2025 →Related reading
Disclaimer: This page is educational information, not medical advice. GLP-1 medications require a licensed clinician evaluation. Always consult a licensed prescriber before starting, changing, or stopping treatment. Compounded GLP-1 medications are not FDA-approved finished drug products.